Evidence map›Paper›PMID 41346604›Full record

ArticleFrontiers in immunology2025

Myeloid PDLIM2 repression as a common mechanism of infection susceptibility in lung diseases.

Feng Gao, Xujie Liu, Fan Sun, Yadong Xiao, Gutian Xiao, Zhaoxia Qu

Abstract read
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. PDLIM2 in lung adenocarcinoma metastasis.Neoplasia (New York, N.Y.) · 2026
    Article
  2. Article
  3. Article
  4. PDLIM2 in Lung Adenocarcinoma Metastasis.bioRxiv : the preprint server for biology · 2025
    Article
  5. PDLIM2 Repression: A Common Mechanism in Viral Lung Infection.bioRxiv : the preprint server for biology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Feng Gao *Department of Molecular Microbiology and Immunology, Hastings Center for Pulmonary Research, Norris Comprehensive Cancer Center, University of Southern California Keck School of Medicine, Los Angeles, CA, United States.
Xujie Liu *Department of Molecular Microbiology and Immunology, Hastings Center for Pulmonary Research, Norris Comprehensive Cancer Center, University of Southern California Keck School of Medicine, Los Angeles, CA, United States.
Fan Sun *Department of Microbiology and Molecular Genetics, UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States.
Yadong XiaoDepartment of Molecular Microbiology and Immunology, Hastings Center for Pulmonary Research, Norris Comprehensive Cancer Center, University of Southern California Keck School of Medicine, Los Angeles, CA, United States.
Gutian XiaoDepartment of Molecular Microbiology and Immunology, Hastings Center for Pulmonary Research, Norris Comprehensive Cancer Center, University of Southern California Keck School of Medicine, Los Angeles, CA, United States.
Zhaoxia QuDepartment of Molecular Microbiology and Immunology, Hastings Center for Pulmonary Research, Norris Comprehensive Cancer Center, University of Southern California Keck School of Medicine, Los Angeles, CA, United States.

Funding

Structural and molecular dissection of NF-kappaB regulation by the ubiquitin E3 ligase PDLIM2 in lung innate immunity and diseasesR01GM144890 · NIGMS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI QU, ZHAOXIA, XIAO, GUTIAN · 2022 to 2025
$2.1M
Mechanistic difference of NF-kappaB in lung physiology and tumorigenesisR01CA258614 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Zhaoxia Qu, GUTIAN XIAO · 2022 to 2026
$1.9M
The NF-kappaB modulator PDLIM2 as an intrinsic checkpoint of alveolar macrophages critical for lung innate immunity, inflammation and diseasesR01HL177140 · NHLBI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Zhaoxia Qu · 2025 to 2026
$1.6M
NCI NIH HHS R01 CA258614NHLBI NIH HHS R01 HL177140NIGMS NIH HHS R01 GM144890
6 · The paper itself

Abstract

Introduction: The PDZ-LIM domain-containing protein PDLIM2 serves as a unique tumor suppressor and immune modulator. Its repression in either lung epithelial or myeloid cells has been shown to promote lung cancer and therapy resistance. However, whether PDLIM2 plays a broader role in other lung diseases remains unclear. Methods: Gene expression data on human samples were exploited to investigate if PDLIM2 is repressed in the lung of patients with chronic obstructive pulmonary disease (COPD) or interstitial lung disease (ILD/idiopathic pulmonary fibrosis (IPF). PDLIM2 conditional knockout (KO) mice and wild type (WT) control mice were intratracheally instilled with the bacterial endotoxin lipopolysaccharide (LPS) to induce acute lung injury (ALI), a murine model of human acute respiratory distress syndrome (ARDS) that can also provide mechanistic insights into COPD, pulmonary fibrosis (PF) and infectious disease. Kaplan-Meier estimator was used to determine animal survival rate, and histological analysis and single-cell RNA sequencing (scRNA-seq) of mouse lung tissues were performed to systematically define the roles of PDLIM2 at the population and single-cell level. Results: PDLIM2 was repressed in the lungs of COPD and ILD/IPF patients, and this repression was associated with disease severity. Selective deletion of PDLIM2 in myeloid cells rendered mice more vulnerable to lung injury and mortality by LPS intratracheal instillation. The increased susceptibility was linked to exacerbated pro-inflammation signaling and diminished anti-inflammation signaling in the lung, and particularly, in lung macrophages and neutrophils. Conclusions: PDLIM2 plays an indispensable role in preventing ALI/ARDS and death, and its repression is associated with COPD and ILD progression. These data suggest that PDLIM2 repression, especially in lung myeloid cells, is a common mechanism driving COPD, ILD/IPF, and lung cancer and increasing patients' susceptibility to infection.

Indexed as

LIM Domain ProteinsLung Diseases, InterstitialMicrofilament ProteinsMyeloid CellsPulmonary Disease, Chronic ObstructiveAdaptor Proteins, Signal TransducingAnimalsDisease Models, AnimalDisease SusceptibilityFemaleHumansIdiopathic Pulmonary FibrosisLipopolysaccharidesLungMaleMiceAdaptor Proteins, Signal TransducingLIM Domain ProteinsLipopolysaccharidesMicrofilament ProteinsPDLIM2 protein, humanPdlim2 protein, mouseCOPDILD/IPFLPSlung cancerlung infectionNF-κBPDLIM2RelA/p65

Identifiers

PMID41346604
PMCPMC12672342

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.